Agreement between diagnoses of childhood lymphoma assigned in Uganda and by an international reference laboratory by Orem, J. et al.
© 2012 Orem et al, publisher and licensee Dove Medical Press Ltd. This is an Open Access article  
which permits unrestricted noncommercial use, provided the original work is properly cited.
Clinical Epidemiology 2012:4 339–347
Clinical Epidemiology
Agreement between diagnoses of childhood 
lymphoma assigned in Uganda and by an 
international reference laboratory
Jackson Orem1–3
Sven Sandin1
Caroline E Weibull1
Michael Odida4
Henry Wabinga4
Edward Mbidde2,3
Fred Wabwire-Mangen5
Chris JLM Meijer6
Jaap M Middeldorp6
Elisabete Weiderpass1,7,8
1Department of Medical Epidemiology 
and Biostatistics, Karolinska Institutet, 
Stockholm, Sweden; 2Uganda Cancer 
Institute, 3School of Medicine, 4School 
of Biomedical Sciences, 5School of 
Public Health, Makerere University 
College of Health Sciences, Kampala, 
Uganda; 6Department of Pathology, 
VU University Medical Center, 
Amsterdam, The Netherlands; 
7Cancer Registry of Norway, Oslo; 
Department of Community Medicine, 
University of Tromsø, Tromsø, 
Norway; 8Samfundet Folkhälsan, 
Helsinki, Finland
Correspondence: Elisabete Weiderpass 
Department of Medical Epidemiology  
and Biostatistics, Karolinska Institutet,  
PO Box 281, 17177 Stockholm, Sweden 
Tel +35 84 0845 3406 
Fax +46 831 1101 
Email elisabete.weiderpass@ki.se
Background: Correct diagnosis is key to appropriate treatment of cancer in children. However, 
diagnostic challenges are common in low-income and middle-income countries. The objective 
of the present study was to assess the agreement between a clinical diagnosis of childhood non-
Hodgkin lymphoma (NHL) assigned in Uganda, a pathological diagnosis assigned in Uganda, 
and a pathological diagnosis assigned in The Netherlands.
Methods: The study included children with suspected NHL referred to the Mulago National 
Referral Hospital, Kampala, Uganda, between 2004 and 2008. A clinical diagnosis was assigned 
at the Mulago National Referral Hospital, where tissue samples were also obtained. Hematoxylin 
and eosin-stained slides were used for histological diagnosis in Uganda, and were re-examined 
in a pathology laboratory in The Netherlands, where additional pathological, virological and 
serological testing was also carried out. Agreement between diagnostic sites was compared 
using kappa statistics.
Results: Clinical and pathological diagnoses from Uganda and pathological diagnosis from 
The Netherlands was available for 118 children. The agreement between clinical and pathological 
diagnoses of NHL assigned in Uganda was 91% (95% confidence interval [CI] 84–95; kappa 
0.84; P , 0.001) and in The Netherlands was 49% (95% CI 40–59; kappa 0.04; P = 0.612). 
When Burkitt’s lymphoma was considered separately from other NHL, the agreement between 
clinical diagnoses in Uganda and pathological diagnoses in Uganda was 69% (95% CI 59–77; 
kappa 0.56; P , 0.0001), and the corresponding agreement between pathological diagnoses 
assigned in The Netherlands was 32% (95% CI 24–41; kappa 0.05; P = 0.326). The agreement 
between all pathological diagnoses assigned in Uganda and The Netherlands was 36% (95% 
CI 28–46; kappa 0.11; P = 0.046).
Conclusion: Clinical diagnosis of NHL in Uganda has a high probability of error compared 
with pathological diagnosis in Uganda and in The Netherlands. In addition, agreement on the 
pathological diagnosis of NHL between Uganda and The Netherlands is very low.
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Introduction
Correct diagnosis is key to appropriate treatment of cancer in general, and particularly 
in children, given that most childhood cancers are treatable and curable.1–3 However, 
diagnostic challenges are common in low-income and middle-income countries such 
as Uganda, where pathological diagnosis is still based on accurate determination of 
tissue architecture by histopathology.4,5 Conversely, additional laboratory tests, such 
as immunohistochemistry and flow cytometry, have become routine in pathology 
laboratories in high-income countries, and allow for more detailed classification, 
especially of hematological malignancies.
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Although there are few subtypes of childhood non-
 Hodgkin lymphoma (NHL), ie, lymphoblastic lymphoma, 
Burkitt’s or Burkitt’s-like lymphoma, and large cell lym-
phoma,  classification is usually challenging,6,7 and obtain-
ing adequate tissue samples for histological or cytological 
diagnosis can be particularly difficult.2 Improper processing 
of materials, such as tissue handling and fixation, is the most 
common hindrance to a correct diagnosis in low-resource 
settings.2 The accuracy of diagnoses is therefore often in 
doubt, and disagreement between pathologists is common.8 
Studies on the agreement between clinical and pathological 
diagnoses in Uganda and other low-income countries have 
not been carried out comprehensively, and the available 
information mainly pertains to adults.9,10
The assignment of appropriate treatment for cancer 
patients in sub-Saharan Africa is problematic, particularly 
for children.9,11 Indeed, appropriate treatment requires cor-
rect diagnosis, and in Uganda pathological diagnosis can 
be expensive, time-consuming, and even when available, 
results may be inconclusive for several reasons, including 
lack of adequate equipment and supplies to perform the 
necessary tests.9 However, even in the absence of a conclu-
sive pathological diagnosis, clinicians must make decisions 
regarding treatment. As a result, initial patient management 
is determined by a combination of clinical, and, when avail-
able, pathological criteria.10,11 Moreover, in most countries 
in Africa, where childhood NHL is relatively common, 
once the treatment process is initiated, no further diagnostic 
refinement is done, mainly due to a lack of expertise, lack 
of appropriate laboratory facilities, and the high cost or 
unavailability of advanced tests.9 Therefore, it is difficult 
to ascertain the extent to which children are being treated 
for NHL without a definitive pathological diagnosis in these 
settings.
The objective of this study was to assess the agreement 
between clinical diagnoses of childhood NHL assigned in 
Uganda, pathological diagnoses assigned in Uganda, and 
pathological diagnoses assigned in a reference laboratory in 
The Netherlands. Our foremost motivations to perform this 
study was to elucidate whether childhood NHL in Uganda 
is underdiagnosed or overdiagnosed using current diagnos-
tic practices and to ascertain the need to introduce more 
advanced diagnostic methods in the country.
Materials and methods
We used data from a case-control study of childhood NHL 
conducted between 2004 and 2008 at the Mulago National 
Referral Hospital (MNRH), Kampala, Uganda. Children with 
suspected childhood tumors were referred to the MNRH for 
evaluation, where they underwent clinical examination and 
were invited to participate in the study. Detailed clinical and 
demographic information was collected by questionnaire. All 
children received a clinical diagnosis at the MNRH, based 
on information on presentation and physical findings on 
clinical examination.
Children with suspected NHL were referred to the Uganda 
Cancer Institute in Kampala for specialized management. If 
the clinical diagnosis of NHL was confirmed at the Uganda 
Cancer Institute, the patient was considered a suspected 
case of NHL. Clinical diagnosis of Burkitt’s lymphoma was 
defined as a diagnosis of NHL with a clinically identifiable 
facial tumor, which is usually typical of Burkitt’s lymphoma. 
It was assumed that children with a clinical diagnosis of NHL 
without information on a facial tumor at clinical examination 
did not have a clinical diagnosis of Burkitt’s lymphoma.
The cancer referral system in Uganda has been previ-
ously described in detail.12 Fresh tissue samples were col-
lected at the Uganda Cancer Institute from all children with 
a suspected clinical diagnosis of NHL. All tissue samples 
were divided into two specimens; one was stored at −80°C 
and the other was submitted to the Department of Pathology, 
Makerere University College of Health Sciences, Kampala, 
Uganda, for diagnosis according to a standardized protocol 
for paraffin-embedded tissue.13,14 Tissue samples were then 
examined morphologically and by hematoxylin and eosin 
staining in Uganda. Because pathology in Uganda is done 
as part of standard hospital procedure, the pathologists 
were not blinded to information on clinical diagnosis.
Biopsy blocks, fresh-frozen tissue samples, and original 
pathological slides that were judged to be of sufficient quality 
and quantity were then submitted for review to the Depart-
ment of Pathology at the VU University Medical Center, 
Amsterdam, The Netherlands, which is an academic center 
of excellence for cancer pathology in Europe, and highly 
specialized in Epstein-Barr and other virus-related cancers. 
Morphological examinations were done in The Netherlands 
on the submitted slides by pathologists with expertise in 
lymphoma. These examinations were performed in a blinded 
manner, with the pathologists in The Netherlands having no 
information about the patients’ clinical or pathological diag-
noses from Uganda. Reporting criteria was based on presence 
of NHL (ie, Burkitt’s lymphoma or other NHL), presence of 
other tumor, or presence of an inflammatory process with 
no tumor. New histological slides were then made from 
all tissue blocks received from Uganda, ie, 5–10 separate 
 parallel sections were cut for hematoxylin and eosin  staining, 
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Epstein-Barr virus-encoded messenger RNA and RNA in situ 
hybridization (EBER-RISH) plus CD10, bcl2 and control 
stainings, including pan-B-cell antigen (CD19), pan-T-
cell antigen (CD3), and cytokeratin-18, with all analyses 
performed using standardized procedures. Tissue samples 
were then subjected to further analysis with EBER-RISH, 
DAKO-PNA probes, and an optimized inhouse detection 
method.15
Results from both pathological laboratories (Uganda 
and The Netherlands) were classified as NHL (ie, Burkitt’s 
lymphoma or other NHL), other cancers, and chronic non-
cancerous conditions. Subtype classification of NHL was 
also performed, and was categorized as Burkitt’s lymphoma 
or other NHL. NHL diagnoses and subtyping were in accor-
dance with the World Health Organization classification of 
hematological malignancies.7
Statistical methods
Agreement between clinical diagnoses at the MNRH, 
pathological diagnoses assigned in Uganda, and pathological 
diagnoses assigned in The Netherlands was established using 
summary statistics and by calculating kappa statistics with 
two-sided 95% confidence intervals (CIs) using bootstrap 
techniques and a two-sided test of the hypothesis of a kappa 
being equal to zero. We calculated the observed agreement 
(percentage of samples rated equally) and two-sided 95% 
exact CIs.16 The kappa statistic measures the agreement 
between two raters by relating the observed proportion of 
equally rated samples with what is expected from chance 
alone, ie, (P
o
 – P
e
)/(1 – P
e
), where P
o
 is the observed proportion 
of samples on which two raters agree and P
e
 is the proportion 
expected by chance alone. A value close to zero indicates 
no agreement while a value close to one indicates good 
 agreement.17 The statistical software R package irr version 
0.83 for Debian-64 bit was used for the kappa calculations.
Results
Between 2004 and 2008, 649 children aged 1–17 years with 
suspected tumors were referred to the MNRH for evaluation. 
Of these, 421 children who had their parents or guardians 
present were invited to participate in the study on childhood 
NHL. Assent was also requested from invited children aged 
9 years or older. Assent was not requested from children aged 
younger than 9 years, because they were considered to be 
too young to understand the procedures; for these children, 
parental or guardian consent was considered sufficient for 
participation. Three hundred and twenty-one children had 
consent from a parent or guardian (and if aged 9 or more years 
assented to participate), and were thus enrolled. Of these 
321 children, 314 had a clinical diagnosis of either a tumor 
or a nontumor condition (clinical diagnosis was missing for 
seven children). Tissue samples were collected from 273 
enrolled children for pathological diagnosis in the Ugandan 
laboratory. Two hundred and thirty-nine of the tissue samples 
used for pathological diagnosis in Uganda were judged to 
be of sufficient quality and quantity and were shipped to 
The Netherlands for confirmatory diagnosis. Upon arrival in 
The Netherlands, 106 (44.4%) of the samples were deemed 
not analyzable because they were either inadequate or poorly 
processed. Of the remaining 133 tissue samples, 129 could be 
conclusively diagnosed. There were 118 children with com-
plete diagnostic information (clinical diagnosis, pathological 
diagnosis assigned in Uganda, and pathological diagnosis 
assigned in The Netherlands), among whom comparisons 
could be made at all levels (Figure 1).
Patient characteristics
Of the 314 children with a clinical diagnosis, 199 (63.4%) 
were boys, 115 (36.6%) were girls, and 13 children were posi-
tive for human immunodeficiency virus. The most common 
symptoms were fever, night sweats, and weight loss. The 
characteristics of the 118 children with complete diagnostic 
information were very similar to those of the 314 children 
with a clinical diagnosis (Table 1). The mean ages of these 
314 and 118 children were 7.2 ± 3.3 (range 1–17) years and 
7.5 ± 3.5 (range 2–17) years, respectively (Figure 2).
Agreement between clinical  
and pathological diagnoses
Agreement on the diagnosis of NHL (ie, Burkitt’s lymphoma 
and other NHL), other cancer, or chronic noncancerous 
conditions between clinical diagnoses and pathological 
diagnoses assigned in Uganda was 91% (95% CI 84–95) 
with a kappa statistic of 0.84 (95% CI 0.75–0.92; P , 0.001). 
The agreement between clinical diagnoses and pathological 
diagnoses assigned in The Netherlands was 49% (95% CI 
40–59) with a kappa statistic of 0.04 (95% CI −0.10–0.17; 
P = 0.612). Of the 46 children with a clinical diagnosis of a 
chronic noncancerous condition, 34 had a cancer diagnosis 
according to the laboratory in The Netherlands (Table 2).
Further comparison by NHL subtype (ie, Burkitt’s 
lymphoma or other NHL), other cancer, or a chronic non-
cancerous condition, showed an agreement between clinical 
diagnoses and pathological diagnoses assigned in Uganda 
of 69% (95% CI 59–77) with a kappa statistic of 0.56 (95% 
CI 0.44–0.67; P , 0.001). Agreement on NHL subtypes 
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(ie, Burkitt’s lymphoma or other NHL), other cancer, and a 
chronic noncancerous condition between clinical diagnoses 
and pathological diagnoses assigned in The Netherlands was 
32% (95% CI 24–41) with a kappa statistic of 0.05 (95% 
CI −0.06–0.16; P = 0.326, Table 3). A direct comparison 
of pathological diagnoses assigned in Uganda and The 
Netherlands showed an agreement of 36% (95% CI 28–46) 
with a kappa value of 0.11 (95% CI −0.01–0.24; P = 0.0459, 
Table 4).
Discussion
In this study, we compared diagnoses assigned by clinicians 
in Uganda who initially enrolled children with suspected 
NHL at the MNRH, and those assigned by pathologists 
in Uganda and The Netherlands using the same tissue 
samples. Pathological diagnosis was based on histology 
using hematoxylin and eosin staining both in Uganda and 
The  Netherlands, whereas diagnoses were further detailed 
by several additional tests in The Netherlands.
Although agreement between clinical diagnoses and 
pathological diagnoses assigned in Uganda was relatively 
high, agreement between clinical diagnoses and patho-
logical diagnoses in The Netherlands was much lower. This 
discrepancy could be partially explained by the fact that the 
pathologists in Uganda were not blinded to information on 
clinical diagnosis, and may therefore have been influenced 
by the clinical diagnosis when in doubt about the pathologi-
cal findings. This was unavoidable given that the study was 
conducted in a routine clinical setting. The pathologists in The 
Netherlands had no access to clinical diagnoses, and based 
their diagnosis solely on the biological samples.
The agreement between pathological diagnoses made in 
Uganda and in The Netherlands was very low (36%). This 
weak agreement is probably due to the fact that pathologi-
cal diagnosis in Uganda is performed at a very basic level, 
whereas pathologists in The Netherlands have access to 
additional tests for subsequent detailed characterization 
by immunohistochemistry, and are thus able to make more 
649 children
228 children excluded as
parents not present
421 children invited
321 children enrolled
118 children with complete diagnostic informationa
38
8
1
2
118
150
3
Overlap of the available
results from the KNRH
and the two pathology
laboratories
314 children with clinical
diagnosis from hospital
in Uganda
100 children excluded due
to lack of parental consent
273 children with results
from pathology in
Uganda available
129 children with results
from pathology in The
Netherlands available
Figure 1 Flow of data for participants of this study on childhood lymphoma at the Mulago National Referral Hospital with details on overlap between the Mulago National 
Referral Hospital and the two pathology laboratories. 
Note: aComplete diagnostic information includes the clinical diagnosis, the pathological diagnosis assigned in Uganda, and the pathological diagnosis assigned in The Netherlands.
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Figure 2 Age distributions of the 314 children (mean age 7.2 ± 3.3 [range 1–17] years) with a clinical diagnosis at Mulago National Reference Hospital in Uganda and the 
118 children (mean age 7.5 ± 3.5 [range 2–17] years) with complete diagnostic information.a
Note: aComplete diagnostic information includes the clinical diagnosis, the pathological diagnosis assigned in Uganda, and the pathological diagnosis assigned in The Netherlands.
Table 2 Comparison of agreement between clinical diagnoses assigned at the Mulago National Referral Hospital in Uganda for non-
Hodgkin lymphoma (including Burkitt’s lymphoma), other cancer, and noncancerous chronic conditions, and the pathology laboratories 
in Uganda and The Netherlands, for the 118 children with complete diagnostic informationa
Clinical diagnosis from Uganda
NHL, n (%) Other cancer, n (%) NCCC, n (%) Total, n (%)
Pathological diagnosis from Uganda
 NHL 58 (94) 1 (2) 3 (5) 62 (100)
 Other cancer 1 (8) 9 (69) 3 (23) 13 (100)
 NCCC 1 (2) 2 (5) 40 (93) 43 (100)
 Total 60 (51) 12 (10) 46 (39) 118 (100)
Kappa test statistic (95% CI) 0.84b (0.75, 0.92)
P value of the kappa statistics ,0.001
Percentage of agreement (95% CI) 91% (84%, 95%)
Pathological diagnosis from The Netherlands
 NHL 46 (53) 8 (9) 33 (38) 87 (100)
 Other cancer 1 (50) 0 (0) 1 (50) 2 (100)
 NCCC 13 (45) 4 (14) 12 (41) 29 (100)
 Total 60 (51) 12 (10) 46 (39) 118 (100)
Kappa test statistic (95% CI) 0.04 (-0.10, 0.17)
P value of the kappa statistics 0.612
Percentage of agreement (95% CI) 49% (40%, 59%)
Notes: aComplete diagnostic information: clinical diagnosis, pathological diagnosis assigned in Uganda and pathological diagnosis assigned in The Netherlands; bwe also 
performed a kappa test result including 268 children with both preliminary clinical diagnosis and pathological diagnosis from Uganda, which yielded a kappa statistic of 0.74 
(95% CI 0.66–0.81; P , 0.0001), and a percentage agreement of 84% (95% CI 79–88). 
Abbreviations: CI, confidence interval; NHL, non-Hodgkin lymphoma; NCCC, noncancerous chronic condition; n, number of children.
 precise diagnoses. Assuming that the diagnoses assigned 
in The Netherlands are correct, which is a fair assumption 
given the state-of-the-art laboratory and highly trained staff 
specialized in the diagnosis of lymphomas, particularly 
Burkitt’s lymphoma, our study indicates that only 52% 
of the children with Burkitt’s lymphoma, and only 22% 
of the children with NHL in Uganda are being correctly 
diagnosed. Inevitably, inappropriate cancer diagnoses lead 
to inadequate patient management, consequently compro-
mising the prognosis.
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Table 3 Comparison of agreement between clinical diagnosis at the Mulago National Referral Hospital in Uganda for Burkitt’s 
lymphoma, other non-Hodgkin lymphoma (excluding Burkitt’s lymphoma), other cancer, and noncancerous chronic conditions, and 
pathology laboratories in Uganda and in The Netherlands, for the 118 children with complete diagnostic informationa
Clinical diagnosis from Uganda Total, n (%)
BLb, n (%) Other NHL, n (%) Other cancer, n (%) NCCC, n (%)
Pathological diagnosis from Uganda
 BL 21 (62) 10 (29) 0 (0) 3 (9) 34 (100)
 Other NHL 16 (57) 11 (39) 1 (4) 0 (09) 28 (100)
 Other cancer 0 (0) 1 (8) 9 (69) 3 (239) 13 (100)
 NCCC 1 (2) 0 (0) 2 (5) 40 (939) 43 (100)
 Total 38 (32) 22 (19) 12 (10) 46 (399) 118 (100)
Kappa test statistic (95% CI) 0.56 (0.44–0.67)
P value of the kappa statistics ,0.0001
Percentage of agreement (95% CI) 69% (59%, 77%)
Pathological diagnosis from The Netherlands
 BL 19 (45) 10 (24) 0 (0) 13 (31) 42 (100)
 Other NHL 10 (22) 7 (16) 8 (18) 20 (44) 45 (100)
 Other cancer 1 (50) 0 (0) 0 (0) 1 (50) 2 (100)
 NCCC 8 (28) 5 (17) 4 (14) 12 (41) 29 (100)
 Total 38 (32) 22 (19) 12 (10) 46 (39) 118 (100)
Kappa test statistic (95% CI) 0.05 (−0.06, 0.16)
P value of kappa statistics 0.326
Percentage of agreement (95% CI) 32% (24%, 41%)
Notes: aComplete diagnostic information: clinical diagnosis, pathological diagnosis assigned in Uganda, and pathological diagnosis assigned in The Netherlands; bcombination 
of variable clinical diagnosis of NHL from Uganda used in Table 2 and “assessment of facial tumor” (“yes” if patient had facial tumor, and “no” otherwise). A patient here is 
classified as BL if she or he had both a clinical diagnosis of NHL and a facial tumor. 
Abbreviations: BL, Burkitt’s lymphoma; NHL, non-Hodgkin lymphoma; NCCC, noncancerous chronic condition; n, number of children.
Table 4 Comparison of agreement between the pathological diagnoses assigned in Uganda and The Netherlands, for the 118 children 
with complete diagnostic informationa
Pathological diagnosis from Uganda Total, n (%)
BL, n (%) Other NHL, n (%) Other cancer, n (%) NCCC, n (%)
Pathological diagnosis from The Netherlands
 BL 22 (52) 7 (17) 1 (2) 12 (29) 42 (100)
 Other NHL 8 (18) 10 (22) 8 (18) 19 (42) 45 (100)
 Other cancer 0 (0) 1 (50) 0 (0) 1 (0) 2 (100)
 NCCC 4 (14) 10 (34) 4 (14) 11 (38) 29 (100)
 Total 34 (29) 28 (24) 13 (11) 43 (36) 118 (100)
Kappa test statistic (95% CI) 0.11 (−0.01, 0.24)
P value of kappa statistics 0.0459
Percentage of agreement (95% CI) 36% (28%, 46%)
Note: aComplete diagnostic information: clinical diagnosis, pathological diagnosis assigned in Uganda and pathological diagnosis assigned in The Netherlands. 
Abbreviations: BL, Burkitt’s lymphoma; CI, confidence interval; NHL, non-Hodgkin lymphoma; NCCC, noncancerous chronic condition; n, number of children.
The strengths of this study include the study setting, 
namely a national cancer treatment center in Kampala and its 
affiliate pathology laboratory, the relatively large sample size, 
and the fact that the pathological diagnoses were based on 
the same tissue samples in Uganda and in The Netherlands. 
Moreover, we were able to compare clinical diagnoses in 
Uganda with histological diagnoses assigned in Uganda and 
in The Netherlands.
The main weaknesses of the study are that a large number 
of patients had to be excluded from the final analysis for 
diverse reasons, and that many tissue samples could not be 
properly analyzed in The Netherlands for technical reasons, 
including poor tissue processing or storage problems back in 
Uganda. Our analysis comparing the 314 children enrolled in 
the study with a clinical diagnosis and the 118 children with 
complete diagnostic information did not reveal significant 
differences in terms of age distribution, prevalence of human 
immunodeficiency virus, or symptoms associated with their 
medical conditions. This is quite reassuring, and suggests 
that no systematic exclusion of a particular group of children 
from the final analysis took place. Still, it could be correctly 
argued that the children included in our study are not a truly 
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representative sample of all children with NHL in Uganda, 
because only the children who actually reached the Uganda 
Cancer Institute (the only specialized cancer hospital in the 
country), had informed consent from a parent or guardian, 
and in addition had a biological sample collected and ana-
lyzed, were included. However, given that the aim of the study 
was to verify the agreement between clinical and pathologi-
cal diagnoses within the hospital population, we could only 
include children with complete diagnostic information in the 
final analyses. Moreover, conclusions were drawn based on 
internal comparisons within the study population only, thus 
internal validity was assured. Although only 118 children 
had complete diagnostic information, a larger number of 
samples would not necessarily have increased the probability 
of agreement across the three diagnostic procedures.
Unfortunately, our findings in Uganda may not be unique. 
A recent survey of infrastructure and capacity for diagnosis 
in Africa indicated an unacceptably low standard of histo-
pathology, probably due to the lack of advanced technology 
and shortage of pathologists.18 It has been suggested that the 
solution to the poor quality of diagnosis in low-income and 
middle-income countries is to form partnerships with centers 
of excellence in high-income countries, where samples can 
be submitted or data and images shared, in particular when 
rapid and high-quality Internet-based digital imaging is 
involved. There is merit to this suggestion, but the downside 
is that it may not improve primary tissue processing expertise, 
and may neglect local capacity building and sustainability. 
Moreover, without a strong infrastructure for obtaining and 
processing good quality samples, the quality of shipped 
slides and samples will still affect the quality of diagnosis.19 
A study from Ghana is instructive in this regard. It evaluated 
the feasibility of using a UK-based diagnostic laboratory to 
improve the diagnosis and management of lymphoprolifera-
tive disorders.9 Although refined diagnoses were achieved, 
the implementation was challenging in Ghana due to lack of 
local capacity and specialized facilities to produce adequate 
samples. Therefore, this study confirms the need for a secure 
local structure that can obtain and process samples, and make 
the initial diagnosis.
The present report provides evidence of a need to improve 
the quality of diagnosis of childhood NHL in Uganda. There 
is a clear need to create an efficient system within the pub-
lic health sector for collecting, handling, processing, and 
storing biological samples. Moreover, there is a need for 
a national reference laboratory specialized in cancer that 
can render dependable clinical histopathology diagnoses. 
This laboratory should be adequately equipped and staffed, 
have reliable access to laboratory supplies, clinical guidelines, 
standard operating procedures, algorithms for diagnosis, 
and regular quality control of all procedures. Such a labora-
tory should be an integral part of the public health system 
in Uganda, and needs to be affordable or free of charge for 
low-income families with children having a suspected cancer 
diagnosis. It could also serve as a national center for con-
tinued medical education and training for pathologists and 
 clinicians.20 In addition, more advanced skills and technology 
for pathological diagnosis, such as basic immunohistochemical 
analysis, should be introduced whenever feasible in tertiary 
hospitals around the country. Clinicians should also be trained 
to provide early leads to pathologists about the possible 
diagnosis, which brings the added advantage of improved 
teamwork. Improvements in the capacity for tissue handling, 
processing, storage, and pathology would also expand the 
clinical and pathological research opportunities for the coun-
try, because it would make available a set of reliable biological 
samples. This would be of particular relevance for research 
on childhood NHL, especially Burkitt’s lymphoma, given that 
Uganda is one of the countries with the highest number of 
incident cases of these diseases.
Conclusion
Clinical diagnosis alone should not be the basis for initiating 
treatment of any type of NHL in Uganda, including Burkitt’s 
lymphoma, because the probability of diagnostic error is 
high. A high-quality national histopathology diagnosis 
laboratory specialized in cancer is warranted in Uganda. 
Clinical diagnosis of NHL in Uganda has a high probabil-
ity of error compared with both pathological diagnosis in 
Uganda and in The Netherlands. The agreement between 
pathological diagnosis for NHL in Uganda and The Neth-
erlands is very low.
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